These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38140062)

  • 41. Shaping markets to benefit global health - A 15-year history and lessons learned from the pentavalent vaccine market.
    Malhame M; Baker E; Gandhi G; Jones A; Kalpaxis P; Iqbal R; Momeni Y; Nguyen A
    Vaccine X; 2019 Aug; 2():100033. PubMed ID: 31384748
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial.
    Chen H; Huang Z; Chang S; Hu M; Lu Q; Zhang Y; Wang H; Xiao Y; Wang H; Ge Y; Zou Y; Cui F; Han S; Zhang M; Wang S; Zhu X; Zhang B; Li Z; Ren J; Chen X; Ma R; Zhang L; Guo X; Luo L; Sun X; Yang X
    Vaccine; 2022 Aug; 40(36):5322-5332. PubMed ID: 35931636
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
    Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
    Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimized development of a candidate strain of inactivated EV71 vaccine and analysis of its immunogenicity in rhesus monkeys.
    Dong C; Wang J; Liu L; Zhao H; Shi H; Zhang Y; Jiang L; Li Q
    Hum Vaccin; 2010 Dec; 6(12):1028-37. PubMed ID: 21150270
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Actual Status of Hospitals as COVID-19 Vaccination Clinics in China and Safety Monitoring of Inactivated Vaccine: A Cross-Sectional Study.
    Huang J; Zhang MQ; Huang MZ; Lin GM
    Disaster Med Public Health Prep; 2022 Aug; 17():e256. PubMed ID: 36017705
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protective efficacy of the Newcastle disease virus genotype VII-matched vaccine in commercial layers.
    Sultan HA; Talaat S; Elfeil WK; Selim K; Kutkat MA; Amer SA; Choi KS
    Poult Sci; 2020 Mar; 99(3):1275-1286. PubMed ID: 32111305
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus.
    Wu CN; Lin YC; Fann C; Liao NS; Shih SR; Ho MS
    Vaccine; 2001 Dec; 20(5-6):895-904. PubMed ID: 11738755
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development and large-scale use of recombinant VP2 vaccine for the prevention of infectious bursal disease of chickens.
    Pitcovski J; Gutter B; Gallili G; Goldway M; Perelman B; Gross G; Krispel S; Barbakov M; Michael A
    Vaccine; 2003 Dec; 21(32):4736-43. PubMed ID: 14585684
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of an inactivated genotype 2b porcine epidemic diarrhea virus vaccine in neonatal piglets.
    Baek PS; Choi HW; Lee S; Yoon IJ; Lee YJ; Lee du S; Lee S; Lee C
    Vet Immunol Immunopathol; 2016 Jun; 174():45-9. PubMed ID: 27185262
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pilot-scale production of inactivated monoglycosylated split H
    Wu CY; Kao SE; Tseng YC; Lin YP; Hou JT; Wu LY; Chiu S; Ma CA; Hsiao PW; Hsiao J; Chen JR
    Antiviral Res; 2023 Aug; 216():105640. PubMed ID: 37263355
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy assessment of an inactivated Tembusu virus vaccine candidate in ducks.
    Zhang L; Li Z; Zhang Q; Sun M; Li S; Su W; Hu X; He W; Su J
    Res Vet Sci; 2017 Feb; 110():72-78. PubMed ID: 28159240
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.
    Ma C; Sun W; Tang T; Jia M; Liu Y; Wan Y; Han J; Rodewald L; Li J; Song Y; Wang Y; Wu D; Wang F; Zheng H; Tang L; Gao GF; Yin Z; An Z
    Vaccine; 2022 May; 40(20):2869-2874. PubMed ID: 35400561
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Technical guidelines for seasonal influenza vaccination in China, 2019-2020].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG), Influenza Vaccination TWG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Nov; 40(11):1333-1349. PubMed ID: 31838802
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protective efficacy of an inactivated vaccine against H9N2 avian influenza virus in ducks.
    Teng Q; Shen W; Liu Q; Rong G; Chen L; Li X; Chen H; Yang J; Li Z
    Virol J; 2015 Sep; 12():143. PubMed ID: 26377565
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Strengthening the influenza vaccine virus selection and development process: Report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014.
    Ampofo WK; Azziz-Baumgartner E; Bashir U; Cox NJ; Fasce R; Giovanni M; Grohmann G; Huang S; Katz J; Mironenko A; Mokhtari-Azad T; Sasono PM; Rahman M; Sawanpanyalert P; Siqueira M; Waddell AL; Waiboci L; Wood J; Zhang W; Ziegler T;
    Vaccine; 2015 Aug; 33(36):4368-82. PubMed ID: 26148877
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of Adjuvanted-Whole Inactivated Virus and Live-Attenuated Virus Vaccines against Challenge with Contemporary, Antigenically Distinct H3N2 Influenza A Viruses.
    Abente EJ; Rajao DS; Santos J; Kaplan BS; Nicholson TL; Brockmeier SL; Gauger PC; Perez DR; Vincent AL
    J Virol; 2018 Nov; 92(22):. PubMed ID: 30185589
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Whole Inactivated Virus and Protein-Based COVID-19 Vaccines.
    Hotez PJ; Bottazzi ME
    Annu Rev Med; 2022 Jan; 73():55-64. PubMed ID: 34637324
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
    Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Allergic reactions to Japanese encephalitis vaccine.
    Plesner AM
    Immunol Allergy Clin North Am; 2003 Nov; 23(4):665-97. PubMed ID: 14753386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.